• ADP-ribosyltransferases, an update on function and nomenclature 

      Lüscher, Bernhard; Ahel, I; Altmeyer, Matthias; Ashworth, Alan; Bai, Peter; Chang, Paul; Cohen, Michael S.; Corda, Daniela; Dantzer, F.; Daugherty, MD; Dawson, TM; Dawson, VL; Deindl, S; Fehr, AR; Feijs, KLH; Filippov, DV; Gagné, JP; Grimaldi, Giulia; Guettler, S; Hoch, NC; Hottiger, MO; Korn, P; Kraus, WL; Ladurner, Andreas G.; Lehtiö, Lari; Leung, AKL; Lord, CJ; Mangerich, A; Matic, Ivan; Matthews, Jason; Moldovan, George-Lucian; Moss, Joel; Natoli, Gioacchino; Nielsen, Michael L.; Niepel, Mario; Nolte, Friedrich; Pascal, John; Paschal, Bryce M; Pawłowski, Krzysztof; Poirier, Guy G; Smith, Susan; Timinszky, Gyula; Wang, Zhao-Qi; Yélamos, José; Xiaochun, Yu; Zaja, Roko; Ziegler, Mathias (Journal article; Peer reviewed, 2021)
      ADP-ribosylation, a modification of proteins, nucleic acids, and metabolites, confers broad functions, including roles in stress responses elicited, for example, by DNA damage and viral infection and is involved in intra- ...
    • PARP-inhibition reprograms macrophages toward an anti-tumor phenotype 

      Wang, Lin; Wang, Dan; Sonzogni, Olmo; Ke, Shizhong; Wang, Qi; Thavamani, Abhishek; Batalini, Felipe; Stopka, Sylwia A.; Regan, Michael S.; Vandal, Steven; Tian, Shengya; Pinto, Jocelin; Cyr, Andrew M.; Bret-Mounet, Vanessa C.; Baquer, Gerard; Eikesdal, Hans Petter; Yuan, Min; Asara, John M.; Heng, Yujing J.; Bai, Peter; Agar, Nathalie Y.R.; Wulf, Gerburg M. (Journal article; Peer reviewed, 2022)
      Poly(ADP)ribosylation inhibitors (PARPis) are toxic to cancer cells with homologous recombination (HR) deficiency but not to HR-proficient cells in the tumor microenvironment (TME), including tumor-associated macrophages ...